C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia

Psychiatry Research

Volumn 190, Issue 1, 2011, Pages 91-97

  Fawzi, Mounir H ^a   Fawzi, Mohab M ^a   Fawzi, Maggie M ^b   Said, Nagwa S ^a  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b Zagazig University   (Egypt)

Author keywords

Antipsychotic free; CRP; Egypt; Inflammation; Negative symptoms; PANSS; Waist circumference

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; EGYPT; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; C-REACTIVE PROTEIN; EGYPT; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 83655163937     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2011.05.010     Document Type: Article

References (43)

1. Abernathy T.J., Avery O.T. The occurrence during acute infections of a protein not normally present in the blood. I. Distribution of the reactive protein in patient's sera and the effect of calcium on the flocculation reaction with C-polysaccharide of pneumococcus. Journal of Experimental Medicine 1941, 73:173-182.
2. Akanji A.O., Ohaeri J.U., Al-Shammri S., Fatania H.R. Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients. Psychiatry Research 2009, 169(1):56-61.
3. Arranz B., Rosel P., Ramírez N., Dueñas R., Fernández P., Sanchez J.M., Navarro M.A., San L. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. Journal of Clinical Psychiatry 2004, 65(10):1335-1342.
4. Baptista T., Dávila A., El Fakih Y., Uzcátegui E., Rangel N.N., Olivares Y., Galeazzi T., Vargas D., Peña R., Marquina D., Villarroel V., Teneud L., Beaulieu S. Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia. International Clinical Psychopharmacology 2007, 22(4):205-211.
5. CAPMAS Statistical Yearbook 2005, Central Agency for Public Mobilization and Statistics, Cairo (Egypt).
6. Carrizo E., Fernández V., Quintero J., Connell L., Rodríguez Z., Mosquera M., Acosta A., Baptista T. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophrenia Research 2008, 103(1-3):83-93.
7. de Koning L., Merchant A.T., Pogue J., Anand S.S. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. European Heart Journal 2007, 28(7):850-856.
8. Dickerson F., Stallings C., Origoni A., Boronow J., Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophrenia Research 2007, 93(1-3):261-265.
9. Fan X., Pristach C., Liu E.Y., Freudenreich O., Henderson D.C., Goff D.C. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Research 2007, 149(1-3):267-271.
10. Fawzi M.H., Fawzi M.M. Help-seeking contacts of a sample of Egyptian patients with a first episode psychosis. XIII World Congress of Psychiatry. September 10-15, 2005, Cairo, Egypt 2005.
11. Fawzi M.H., Fawzi M.M., Khedr H., Fawzi M. Tobacco smoking in Egyptian schizophrenia patients with and without obsessive-compulsive symptoms. Schizophrenia Research 2007, 95:236-246.
12. Fawzi M.M., Khedr H., Said N.S., Fawzi M. Metabolic syndrome and serum level of adiponectin in Egyptian patients with schizophrenia. Current Psychiatry 2007, 14(3):387-406.
13. First M.B., Gibbon M., Spitzer R.L., Williams G.B.W. User's Guide for the Structured Interview for DSM-IV Axis I Disorders - Research Version (SCID-I, Version 2.0, February 1996 Final Version) 1996, Biometrics Research, New York.
14. Gach O., Legrand V., Biessaux Y., Chapelle J.P., Vanbelle S., Pierard L.A. Long-term prognostic significance of high-sensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris. American Journal of Cardiology 2007, 99(1):31-35.
15. Glassman A.H., Miller G.E. Editorial. Where there is depression, there is inflammation. . . sometimes. Biological Psychiatry 2007, 62(4):280-281.
16. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine 2009, 71(2):171-186.
17. International Diabetes Federation The IDF consensus worldwide definition of the metabolic syndrome 2005, International Diabetes Federation, Brussels (Belgium).
18. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13(2):261-276.
19. Kidd P.M. Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. Alternative Medicine Review 2007, 12(3):207-227.
20. Kling M.A., Alesci S., Csako G., Costello R., Luckenbaugh D.A., Bonne O., Duncko R., Drevets W.C., Manji H.K., Charney D.S., Gold P.W., Neumeister A. Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biological Psychiatry 2007, 62(4):309-313.
21. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. British Journal of Psychiatry Suppl 2004, 47:S64-S66.
22. Lakoski S.G., Cushman M., Criqui M., Rundek T., Blumenthal R.S., D'Agostino R.B., Herrington D.M. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. American Heart Journal 2006, 152(3):593-598.
23. Lindenmayer J.P., Nathan A.M., Smith R.C. Hyperglycemia associated with the use of atypical antipsychotics. Journal of Clinical Psychiatry 2001, 62(Suppl. 23):S30-S38.
24. Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychiatry 1997, 58:538-546.
25. Meyer J.M., McEvoy J.P., Davis V.G., Goff D.C., Nasrallah H.A., Davis S.M., Hsiao J.K., Swartz M.S., Stroup T.S., Lieberman J.A. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry 2009, 66(11):1013-1022.
26. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry 2009, 65(9):732-741.
27. Morera A.L., Henry M., García-Hernández A., Fernández-López L. Acute phase proteins as biological markers of negative psychopathology in paranoid schizophrenia. Actas Españolas de Psiquiatría 2007, 35(4):249-252.
28. Müller N. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Current Opinion in Investigational Drugs 2010, 11(1):31-42.
29. Ohaeri J.U., Hedo C.C., Enyidah S.N., Ogunniyi A.O. Tissue Injury-Inducing Potential of Unmodified ECT: Serial Measurement of Acute Phase Reactants. Convulsive Therapy 1992, 8(4):253-257.
30. Ohaeri J.U., Hedo C.C., Lagundoye O.O. The profile of C-reactive proteins in functional psychotic states in a cohort in Nigeria. Acta Psychiatrica Scandinavica 1993, 88(4):252-255.
31. Palmer B.W., Dunn L.B., Appelbaum P.S., Mudaliar S., Thal L., Henry R., Golshan S., Jeste D.V. Assessment of capacity to consent to research among older persons with schizophrenia, Alzheimer disease, or diabetes mellitus: comparison of a 3-item questionnaire with a comprehensive standardized capacity instrument. Archives of General Psychiatry 2005, 62(7):726-733.
32. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological Psychiatry 2008, 63(8):801-808.
33. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. American Journal of Psychiatry 2003, 160:284-289.
34. Saito M., Ishimitsu T., Minami J., Ono H., Ohrui M., Matsuoka H. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 2003, 167(1):73-79.
35. Sarandol A., Kirli S., Akkaya C., Ocak N., Eroz E., Sarandol E. Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment. Journal of Psychopharmacology 2007, 21(8):857-863.
36. Schuster D.P. Changes in physiology with increasing fat mass. Seminars in Pediatric Surgery 2009, 18(3):126-135.
37. Spelman L.M., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabetic Medicine 2007, 24:481-485.
38. SPSS for Windows Statistical Package for the Social Sciences (Version 11.5) 2001, SPSS Inc., Chicago.
39. Taylor A.W., Ku N.O., Mortensen R.F. Regulation of cytokine-induced human C-reactive protein production by transforming growth factor-beta. Journal of Immunology 1990, 145(8):2507-2513.
40. Thakore J.H., Mann J.N., Vlahos I., Martin A., Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. International Journal of Obesity and Related Metabolic Disorders 2002, 26(1):137-141.
41. Tomiyama R. Factors interfering with CRP assay (from the manufacturer's perspective). The Japanese journal of clinical pathology (Rinsho byori) 2000, 48(8):760-763.
42. Venkatasubramanian G., Chittiprol S., Neelakantachar N., Shetty T., Gangadhar B.N. Effect of antipsychotic treatment on insulin-like growth factor-1 and coirtisol in schizophrenia: a longitudinal study. Schizophrenia Research 2010, 119(1-3):131-137.
43. Verma S., Yeh E.T. C-reactive protein and atherothrombosis-beyond a biomarker: an actual partaker of lesion formation. American Journal of Physiology -Regulatory, Integrative and Comparative Physiology 2003, 285:R1253-R1256.